Lauren Grygotis, Editor

Data do not support the use of an MRI-guided treat-to-target strategy for treating patients with rheumatoid arthritis.

The ACR is urging CMS to adopt safeguards to protect Medicare Advantage beneficiaries from step therapy.

Pelvic orientation was adjusted by global spinal alignment in patients with ankylosing spondylitis.

The American College of Rheumatology and Association of Physicians of Great Britain and Ireland have highlighted unmet needs and challenges of connective tissue disease-associated interstitial lung disease.

The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of osteoarthritis.

Health and social service utilization decreased in immigrant communities after the 2016 presidential election.

The ACR and EULAR have developed draft classification criteria for giant cell arteritis and Takayasu arteritis.

Treatment with filgotinib over 24 weeks resulted in significant improvements in the signs and symptoms of RA among patients with inadequate response or intolerance to biologic DMARDs.

Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.

The genetic risk score may have lower costs than current testing methods.

Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.

Real-time patient input about treatment satisfaction can improve management strategies in patients with rheumatoid arthritis.

Patients generally experienced pain relief over 5 years regardless of whether they received physical therapy or arthroscopic partial menisectomy.

The ACR/ARHP 2018 annual meeting will take place from Saturday, October 19, through Wednesday, October 24, in Chicago, Illinois.

Researchers examined the use of dual-energy computed tomography gout imaging in clinical practice from 2007 to 2016.

The ASBMR Secondary Fracture Prevention Initiative Coalition outlined recommendations to improve efforts to increase diagnosis and treatment of individuals who are at high risk for osteoporosis.

The risk for subsequent osteoporotic fracture was elevated for both sexes over a 25-year follow-up period.

Although a combination of lesinurad 200 mg and xanthine oxidase inhibitor therapy was effective and well-tolerated among patients with gout, clinical gout-related benefits were not improved.

TNFi treatment is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis

Data indicate that drug-naive new onset systemic lupus erythematosus was likely to involve silent cardiac impairment.

The FDA has released a Biosimilar Action Plan to promote competition and affordability across the market for biologic and biosimilar products.

Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.

A pooled analysis compared the efficacy and safety of anti-TNF biosimilars with their reference products.

Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.

Erythrocyte-bound C4d may be useful in monitoring systemic lupus erythematosus.

The FDA has withdrawn draft guidance intended to provide advice regarding the evaluation of analytical similarity between a biosimilar and a reference product.

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Baricitinib 4 mg was safe and effective in patients with systemic lupus erythematosus.

Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.

Researchers sought to determine whether a treat-to-target strategy based on MRI assessments targeting absence bone marrow edema would lead to improved clinical and radiographic outcomes.